In those HLA transgenic mouse experiments, the combination of AAV8-CD4-CD8 epitopes-CXCL-11-IL-2 and AAV8-CD4-CD8 epitopes-CXCL-11-IL-15 prime/pull/keep vaccine gives the best protection against recurrent eye disease in the UV-B-treated mouse model. Here, CD8A is linked to eye disorder.